First Launch Of GW's Nimbex Muscle Relaxant

5 February 1996

Glaxo Wellcome's new neuromuscular blocking agent Nimbex (cisatracurium besylate) has been launched in the UK, its first market. The product is indicated for use in general anesthesia to facilitate tracheal intubation and to provide muscle relaxation during surgery or mechanical ventilation. The drug is suitable for use all types of procedures and in all types of patient, owing to its unique characteristics.

Cisatracurium is a single-isomer form of GW's established neuromuscular blocker Tracrium (atracurium), and like its parent is a non-depolarizing agent, competing with acetylcholine for receptor sites at the level of the post-junctional membrane.

Before the introduction of atracurium and a related compound, vecuronium, in 1982 neuromuscular blockade was achieved using either depolarizing agents, ie suxamethonium, which offered rapid induction and a short duration of action, or older non-depolarizing drugs with a long duration of action and more side effects. Atracurium was well-received as it had an intermediate duration of action, so that patients would regain muscle and breathing control fairly quickly, but more importantly was metabolized independently of the liver or kidneys (a phenomenon known as Hofmann or spontaneous elimination). This meant that there was no need for dosage adjustment if the patient had impaired renal or hepatic function.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight